BioMarin Pharmaceutical Now Covered by Credit Suisse (BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 3.08% on Thursday, hitting $68.32. 1,071,747 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 52 week low of $55.04 and a 52 week high of $84.25. The stock’s 50-day moving average is $65.00 and its 200-day moving average is $65.28. The company’s market cap is $10.051 billion.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings data on Wednesday, July 30th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.18. The company had revenue of $191.70 million for the quarter, compared to the consensus estimate of $159.70 million. During the same quarter in the previous year, the company posted ($0.16) earnings per share. The company’s revenue for the quarter was up 40.1% on a year-over-year basis. Analysts expect that BioMarin Pharmaceutical will post $-1.30 EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, CFO Daniel K. Spiegelman sold 16,000 shares of BioMarin Pharmaceutical stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $69.83, for a total value of $1,117,280.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Separately, analysts at Nomura raised their price target on shares of BioMarin Pharmaceutical from $77.00 to $82.00 in a research note on Thursday, July 31st. They now have a “neutral” rating on the stock. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $83.25.
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.